On September 15, Eli Lilly announced top-line results from TRIUMPH-2, a Phase 3 trial of investigational retatrutide in adults with obesity or overweight and type 2 diabetes. Lilly reported that participants receiving retatrutide achieved up to 49.6 pounds (22.5 kilograms), or 20.8%, average body-weight reduction at 80 weeks, alongside an average A1C reduction of up to 1.6%. The announcement is a substantive late-stage clinical-research update. However, the figures are company-reported top-line results rather than data from a newly published peer-reviewed paper, a distinction that matters when interpreting this week’s news. [1]

ClinicalTrials.gov identifies TRIUMPH-2 as NCT05929079, a randomized, double-blind, placebo-controlled Phase 3 study of LY3437943 in participants with type 2 diabetes and obesity or overweight. The registry lists 1,152 enrolled participants and records the trial as completed on June 16, 2026. Its official title and protocol information corroborate the study’s design, population, sponsor, and completed status. The registry does not independently supply the newly reported 80-week figures; those specific results are attributed in this article to Lilly’s September 15 disclosure. [2]

Retatrutide is a single investigational molecule designed to activate GIP, GLP-1, and glucagon receptors. HAUZ Research previously covered the scientific rationale for this triple-agonist approach; the TRIUMPH-2 disclosure is distinct because it reports a specific late-stage trial result in a defined study population. Lilly has scheduled an EASD-sponsored symposium for September 30 to present the Phase 3 findings. That presentation is an important next checkpoint, where investigators and the research community can evaluate fuller methods, data tables, and the context surrounding the initial announcement. [1]

The release also provides important boundaries for interpreting the news. Lilly describes retatrutide as investigational and says it is legally available only to participants in its clinical trials. Its announcement notes that the stated results use an efficacy estimand, a prespecified analytical approach that estimates outcomes under stated trial assumptions. A top-line announcement should therefore not be conflated with a complete evidence package: further detail on safety, discontinuations, subgroup analyses, and statistical context is needed for a full scientific assessment. No human-use, dosing, or administration guidance is implied by this research update. [1]

For peptide and metabolic-research observers, TRIUMPH-2 is noteworthy because it moves the public evidence conversation from mechanism-level interest to a completed Phase 3 dataset. The report does not establish an approved use of retatrutide, nor does it replace independent review or regulatory evaluation. Instead, it offers a new, source-documented reference point for researchers tracking how multi-receptor peptide agonism is being examined in late-stage clinical development. Within the current research-peptide landscape, that is a materially different story from a general triple-agonist overview and a development that merits close, evidence-focused follow-up.

References: [1] Eli Lilly and Company, Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, September 15, 2026: https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-foundayo-retatrutide-and-eloratzp-easd [2] ClinicalTrials.gov, NCT05929079: https://clinicaltrials.gov/study/NCT05929079